First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.

mutations are common in non-small cell lung cancer (NSCLC) and are associated with patient prognosis; however, targeting has faced various difficulties. Currently, immunotherapy, chemotherapy, and chemoimmunotherapy play pivotal roles in the first-line treatment of -mutated NSCLC. Here, we summarize the current evidence on first-line therapies and compare the treatment outcomes and biomarkers for different regimens. KRAS inhibitors and other emerging alternative treatments are also discussed, as combining these drugs with immunotherapy may serve as a promising first-line treatment for -mutated NSCLC in the future. We hope that this review will assist in first-line treatment choices and shed light on the development of novel agents for -mutated NSCLC.